This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page introduces a 2017 study in which 12 healthy adults received research psilocybin orally and the active metabolite psilocin was measured in plasma and urine to characterize pharmacokinetics. It was not a trial of clinical efficacy, but a small foundational clinical study describing absorption, conversion, and elimination in the body.
Psilocybin is converted to psilocin in the body and is associated with subjective effects. Pharmacokinetic values are averages under research conditions and do not predict every difference arising from constituent amounts in mushrooms, individual metabolism, food, concomitant medications, or liver and kidney function.
Study design
Participants were screened for health status and underwent several escalating conditions. Blood and urine were collected over time during each session, and psilocin was quantified using sensitive liquid chromatography and mass spectrometry. Researchers calculated peak blood concentration, time to peak, elimination half-life, area under the concentration-time curve, and other parameters.
There was no blinding or control group because the purpose was to describe pharmacokinetics. A sample of 12 is too small to encompass individual variation, rare metabolic abnormalities, or safety.
Content
Pharmacokinetics shows how much of a compound was present in the body, but it is not the same as what an experience was like or whether there was a therapeutic effect. The relationship between blood psilocin concentrations and subjective effects varies among people, so psychological responses cannot be predicted from measurements alone.
Standardized oral psilocybin and whole mushrooms differ in absorption conditions and constituent composition. Psilocybin amounts vary by species, individual specimen, storage, and preparation, making it inappropriate to convert the values in this study to mushrooms.
Results
The analyses showed plasma psilocin concentrations rising and then declining after psilocybin administration. Exposure tended to increase across conditions, pharmacokinetic parameters were calculated, and urinary excretion was measured, providing foundational information on metabolism and elimination.
The findings are useful for constructing models of movement through the body and planning monitoring in later trials, but they do not identify a safe threshold for an individual. Average concentration-time profiles and risks such as acute anxiety or changes in blood pressure require separate assessment.
Limitations
This was an open-label study in 12 healthy, selected participants and cannot be generalized to people with psychiatric or physical illness, older adults, pregnancy, or those using concomitant medications. It had limited power to estimate variation among participants and sessions precisely.
The study used a pure research compound and did not assess mushroom products, other constituents, misidentification, or contamination. Pharmacokinetic values alone cannot determine efficacy or long-term safety.
Under escalating conditions, experience from an earlier session may influence subjective ratings and expectations in a later one. Even if the direct effect on pharmacokinetic measurement is small, it cannot be ignored when interpreting safety and experience. If the true peak occurred between blood draws, estimates also contain error.
Safety
Information that a compound disappears from the body relatively quickly does not mean psychological effects end completely on the same timeline. Judgment, perception, blood pressure, heart rate, and anxiety may change during acute effects. Individual metabolism and interactions may also alter exposure.
This page provides no amount calculations or ingestion methods. Pharmacokinetic research should be read as foundational data from controlled research, not repurposed to design self-experimentation.
Source and rights
Original source: Brown RT, et al. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clinical Pharmacokinetics. 2017;56:1543–1554. DOI: 10.1007/s40262-017-0540-6.
Respecting the publisher’s copyright, this page is a detailed introduction that independently summarizes research purpose, methods, results, and limitations based on public bibliographic information and the abstract. It does not reproduce a full translation, pharmacokinetic tables, or figures.